These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28889231)

  • 1. Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.
    Kinoshita M; Okayama H; Kosaki T; Hosokawa S; Kawamura G; Shigematsu T; Takahashi T; Kawada Y; Hiasa G; Yamada T; Matsuoka H; Kazatani Y
    Heart Vessels; 2018 Feb; 33(2):163-169. PubMed ID: 28889231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Heart Vessels; 2018 Apr; 33(4):367-373. PubMed ID: 29128961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan.
    Nomoto H; Satoh Y; Kamiyama M; Yabe K; Masumura M; Sakakibara A; Yamashita S; Suzuki M; Sugiyama T; Oumi T; Ohno M; Takahashi Y; Isobe M
    Int Heart J; 2017 Aug; 58(4):593-600. PubMed ID: 28701677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
    Nishino M; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Egami Y; Tanouchi J
    Int Heart J; 2022; 63(1):85-90. PubMed ID: 35095082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
    Morita Y; Endo A; Kagawa Y; Yamaguchi K; Sato H; Ouchi T; Watanabe N; Tanabe K
    Heart Vessels; 2021 Jun; 36(6):836-843. PubMed ID: 33527152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.
    Adachi S; Miura SI; Shiga Y; Arimura T; Morii J; Kuwano T; Kitajima K; Iwata A; Morito N; Fujimi K; Yahiro E; Nishikawa H; Saku K
    Int Heart J; 2017 May; 58(3):385-392. PubMed ID: 28484118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
    Matsumura K; Morishita S; Taniguchi N; Takehana K; Takahashi H; Otagaki M; Yoshioka K; Yamamoto Y; Takagi M; Shiojima I
    Heart Vessels; 2019 Apr; 34(4):607-615. PubMed ID: 30386917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.
    Shirakabe A; Hata N; Yamamoto M; Kobayashi N; Shinada T; Tomita K; Tsurumi M; Matsushita M; Okazaki H; Yamamoto Y; Yokoyama S; Asai K; Shimizu W
    Circ J; 2014; 78(4):911-21. PubMed ID: 24553192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.